High Free Cash Flow Stocks
PBH is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Price & Overview
NYSE:PBH • US74112D1019
Current stock price
55.57 USD
+0.01 (+0.02%)
Last:
The current stock price of PBH is 55.57 USD. Today PBH is up by 0.02%. In the past month the price decreased by -15.05%. In the past year, price decreased by -32.34%.
PBH Key Statistics
52-Week Range51.24 - 89.37
Current PBH stock price positioned within its 52-week range.
1-Month Range51.24 - 65.6
Current PBH stock price positioned within its 1-month range.
- Market Cap
- 2.63B
- P/E
- 12.40
- Fwd P/E
- 11.47
- EPS (TTM)
- 4.48
- Dividend Yield
- N/A
PBH Stock Performance
Today
+0.02%
1 Week
-6.26%
1 Month
-15.05%
3 Months
-13.42%
Longer-term
6 Months -8.92%
1 Year -32.34%
2 Years -22.58%
3 Years -9.70%
5 Years +27.55%
10 Years -2.15%
PBH Stock Chart
PBH Stock Screens
PBH currently appears in the following ChartMill screener lists.
Low P/E Stocks
PBH is currently part of our Low P/E Stocks screen, indicating it cheap while it also meets financial health criteria.
Value Stocks with Strong Balance Sheets
PBH is currently part of our value stocks with Strong Balance Sheets screen, indicating it cheap while meeting strict financial health and debt criteria.
PBH Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PBH. When comparing the yearly performance of all stocks, PBH is a bad performer in the overall market: 86.75% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
PBH Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PBH. PBH has an excellent profitability rating, but there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PBH Earnings
On February 5, 2026 PBH reported an EPS of 1.14 and a revenue of 283.44M. The company missed EPS expectations (-1.36% surprise) and missed revenue expectations (-0.49% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 5, 2026
PeriodQ3 / 2026
EPS Reported$1.14
Revenue Reported283.44M
EPS Surprise -1.36%
Revenue Surprise -0.49%
PBH Forecast & Estimates
10 analysts have analysed PBH and the average price target is 79.76 USD. This implies a price increase of 43.54% is expected in the next year compared to the current price of 55.57.
For the next year, analysts expect an EPS growth of 1.25% and a revenue growth -2.54% for PBH
Analysts
Analysts84
Price Target79.76 (43.53%)
EPS Next Y1.25%
Revenue Next Year-2.54%
PBH Groups
Sector & Classification
PBH Financial Highlights
Over the last trailing twelve months PBH reported a non-GAAP Earnings per Share(EPS) of 4.48. The EPS increased by 6.92% compared to the year before.
Income Statements
Revenue(TTM)1.10B
Net Income(TTM)186.50M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.9% | ||
| ROA | 5.34% | ||
| ROE | 10.19% | ||
| Debt/Equity | 0.58 |
Chartmill High Growth Momentum
EPS Q2Q%-6.56%
Sales Q2Q%-2.37%
EPS 1Y (TTM)6.92%
Revenue 1Y (TTM)-1.31%
PBH Ownership
Ownership
Inst Owners110.56%
Shares47.32M
Float46.69M
Ins Owners1.33%
Short Float %5.35%
Short Ratio5.58
PBH Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.05 | 899.305B | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 581.198B | ||
| MRK | MERCK & CO. INC. | 23.85 | 304.549B | ||
| PFE | PFIZER INC | 9.16 | 156.259B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.32 | 120.559B | ||
| ZTS | ZOETIS INC | 16.63 | 50.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.3 | 27.632B | ||
| VTRS | VIATRIS INC | 5.39 | 15.624B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.11 | 11.733B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.859B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.705B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.077B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.13 | 4.454B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PBH
Company Profile
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
Company Info
IPO: 2005-02-10
PRESTIGE CONSUMER HEALTHCARE
660 White Plains Rd.
Tarrytown NEW YORK 10591 US
CEO: Ronald M. Lombardi
Employees: 600
Phone: 19145246800
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What does PRESTIGE CONSUMER HEALTHCARE do?
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
Can you provide the latest stock price for PRESTIGE CONSUMER HEALTHCARE?
The current stock price of PBH is 55.57 USD. The price increased by 0.02% in the last trading session.
What is the dividend status of PRESTIGE CONSUMER HEALTHCARE?
PBH does not pay a dividend.
How is the ChartMill rating for PRESTIGE CONSUMER HEALTHCARE?
PBH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting PBH stock to perform?
10 analysts have analysed PBH and the average price target is 79.76 USD. This implies a price increase of 43.54% is expected in the next year compared to the current price of 55.57.
What sector and industry does PRESTIGE CONSUMER HEALTHCARE belong to?
PRESTIGE CONSUMER HEALTHCARE (PBH) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the market cap for PRESTIGE CONSUMER HEALTHCARE?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a market capitalization of 2.63B USD. This makes PBH a Mid Cap stock.